Sarepta Therapeutics (SRPT) Offering Seeing High Demand, Expected to Price at Modest Discount - Feurstein
- Oil edges up ahead of U.S. data, OPEC squabbles cap gains
- DuPont (DD) Tops Q3 EPS by 14c; Boosts FY16 EPS Outlook; Says Continuing to Work with Regulators
- Visa (V) Tops Q4 EPS by 5c
- Rambus (RMBS) Tops Q3 EPS by 3c; Issues Q4 Outlook
- After-Hours Stock Movers 10/24: (SAEX) (CWEI) (RMBS) Higher; (SONC) (WNC) (EFII) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) offering well oversubscribed, upsized and seen pricing at a modest discount to close. - Adam Feurstein.
$SRPT latest chatter on offering: well oversubscribed, upsizing, will price at modest discount to close.— Adam Feuerstein (@adamfeuerstein) September 22, 2016
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Target of Cautious Article
- UPDATE: Cvent, Inc. (CVT) Active on Reports of DOJ Probe into Deal
- FDA Advises Patients With St. Jude Medical (STJ) Heart Implants to Continue Using Devices - Reuters
Create E-mail Alert Related CategoriesFDA, Rumors, Trader Talk
Related EntitiesAdam Feuerstein
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!